Grail (NASDAQ:GRAL – Get Free Report) posted its earnings results on Thursday. The company reported ($1.86) EPS for the quarter, beating the consensus estimate of ($4.41) by $2.55, Zacks reports.
Grail Stock Down 9.2 %
Shares of NASDAQ GRAL traded down $4.84 during trading hours on Thursday, reaching $47.76. The stock had a trading volume of 1,560,490 shares, compared to its average volume of 1,459,752. The firm has a 50-day moving average of $25.78 and a 200-day moving average of $18.86. Grail has a fifty-two week low of $12.33 and a fifty-two week high of $63.99.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently weighed in on the company. Wolfe Research started coverage on Grail in a research report on Friday, November 15th. They set a “peer perform” rating on the stock. Morgan Stanley began coverage on shares of Grail in a report on Wednesday, November 27th. They set an “equal weight” rating and a $16.00 price objective on the stock.
Grail Company Profile
GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.
See Also
- Five stocks we like better than Grail
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- Investing in Construction Stocks
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- 3 Warren Buffett Stocks to Buy Now
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Grail Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grail and related companies with MarketBeat.com's FREE daily email newsletter.
